MET Exon 14 skipping mutations occur in about 3-4% of patients with non-small-cell lung cancer (NSCLC), they in the absence of other driver mutations are generally associated with a poor prognosis. Since 2022, Russia has registered capimanib, the first and the only MET tyrokinase inhibitor designed to treat patients with NSCLC with Exon 14 deletion in the MET gene. This paper provides a clinical case of using capimatinib in the first-line therapy in a patient with NSCLC. Targeted therapy gives a complete response to treatment; the progression-free survival was 22 months